Penetration of Cefpodoxime Proxetil in Lung Parenchyma and Epithelial Lining Fluid of Noninfected Patients

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 1992 Oct 1

PMID 1444291

Citations 7

Authors

C Muller-Serieys

C Bancal

M C Dombret

P Soler

G Murciano

M Aubier

E Bergogne-Berezin

Affiliations

Soon will be listed here.

Abstract

The pulmonary disposition of cefpodoxime was studied in 12 patients with pulmonary opacities after a single oral dose of 260 mg of cefpodoxime-proxetil, which is equivalent to 200 mg of cefpodoxime. Blood and lung tissue samples were collected during surgery, and bronchoalveolar lavage was carried out 3 h (group A) or 6 h (group B) after drug administration. Urea was used as an endogenous marker for measurement of the volume of epithelial lining fluid (ELF). Concentrations were measured by using a microbiological assay. The mean concentrations of cefpodoxime in plasma, ELF, and lung tissue were, respectively, 1.85 +/- 0.82 mg/liter, 0.22 +/- 0.13 mg/liter, and 0.89 +/- 0.80 mg/kg of body weight in group A and 1.40 +/- 1.25 mg/liter, 0.12 +/- 0.14 mg/liter, and 0.84 +/- 0.61 mg/kg in group B. Concentrations in lung parenchyma 6 h after dosing were at least equal to or above the MICs for 90% of the strains of most organisms commonly found in respiratory tract infections, whereas data for ELF suggest levels of drug insufficient to inhibit bacteria.

Citing Articles

Biological Obstacles for Identifying - Correlations of Orally Inhaled Formulations.

Frohlich E Pharmaceutics. 2019; 11(7).

PMID: 31284402 PMC: 6680885. DOI: 10.3390/pharmaceutics11070316.

Penetration of anti-infective agents into pulmonary epithelial lining fluid: focus on antibacterial agents.

Rodvold K, George J, Yoo L Clin Pharmacokinet. 2011; 50(10):637-64.

PMID: 21895037 DOI: 10.2165/11594090-000000000-00000.

Pharmacokinetics and pharmacodynamics of newer oral cephalosporins: implications for treatment of community-acquired lower respiratory tract infections.

Cazzola M, Matera M, Donner C Clin Drug Investig. 2008; 16(4):335-46.

PMID: 18370555 DOI: 10.2165/00044011-199816040-00008.

Lung microdialysis--a powerful tool for the determination of exogenous and endogenous compounds in the lower respiratory tract (mini-review).

Zeitlinger M, Muller M, Joukhadar C AAPS J. 2005; 7(3):E600-8.

PMID: 16353939 PMC: 2751264. DOI: 10.1208/aapsj070362.

Bronchopulmonary disposition of the ketolide telithromycin (HMR 3647).

Muller-Serieys C, Soler P, Cantalloube C, Lemaitre F, Gia H, Brunner F Antimicrob Agents Chemother. 2001; 45(11):3104-8.

PMID: 11600363 PMC: 90789. DOI: 10.1128/AAC.45.11.3104-3108.2001.

References

Valcke Y, Pauwels R, VAN DER STRAETEN M . Pharmacokinetics of antibiotics in the lungs. Eur Respir J. 1990; 3(6):715-22. View

Kroening U, Liebig S, Wundschock M . [Tobramycin Concentration in Human Lung Tissue (author's transl)]. Infection. 1978; 6(5):231-5. DOI: 10.1007/BF01642315. View

ONeill P, Nye K, Douce G, Andrews J, Wise R . Pharmacokinetics and inflammatory fluid penetration of cefpodoxime proxetil in volunteers. Antimicrob Agents Chemother. 1990; 34(2):232-4. PMC: 171563. DOI: 10.1128/AAC.34.2.232. View

Valcke Y, Rosseel M, Pauwels R, Bogaert M, Van der Straeten M . Penetration of ampicillin and sulbactam in the lower airways during respiratory infections. Antimicrob Agents Chemother. 1990; 34(6):958-62. PMC: 171737. DOI: 10.1128/AAC.34.6.958. View

Knapp C, Sierra-Madero J, Washington J . Antibacterial activities of cefpodoxime, cefixime, and ceftriaxone. Antimicrob Agents Chemother. 1988; 32(12):1896-8. PMC: 176041. DOI: 10.1128/AAC.32.12.1896. View

Rennard S, BASSET G, Lecossier D, ODonnell K, Pinkston P, Martin P . Estimation of volume of epithelial lining fluid recovered by lavage using urea as marker of dilution. J Appl Physiol (1985). 1986; 60(2):532-8. DOI: 10.1152/jappl.1986.60.2.532. View

Chastre J, Brun P, Fourtillan J, Soler P, BASSET G, Manuel C . Pulmonary disposition of roxithromycin (RU 28965), a new macrolide antibiotic. Antimicrob Agents Chemother. 1987; 31(9):1312-6. PMC: 174933. DOI: 10.1128/AAC.31.9.1312. View

Taulier A, P Levillain , LEMONNIER A . [Value of derivative spectrophotometry for the determination of plasma and urinary hemoglobin. Comparison with the method using Allen's correction]. Ann Biol Clin (Paris). 1986; 44(3):242-8. View

Braude A, Hornstein A, Klein M, Vas S, Rebuck A . Pulmonary disposition of tobramycin. Am Rev Respir Dis. 1983; 127(5):563-5. DOI: 10.1164/arrd.1983.127.5.563. View

10.

Hunninghake G, Gadek J, Kawanami O, Ferrans V, Crystal R . Inflammatory and immune processes in the human lung in health and disease: evaluation by bronchoalveolar lavage. Am J Pathol. 1979; 97(1):149-206. PMC: 2042387. View

11.

Couraud L, Andrews J, Lecoeur H, Sultan E, Lenfant B . Concentrations of cefpodoxime in plasma and lung tissue after a single oral dose of cefpodoxime proxetil. J Antimicrob Chemother. 1990; 26 Suppl E:35-40. DOI: 10.1093/jac/26.suppl_e.35. View

12.

Wise R, Andrews J, Ashby J, Thornber D . The in-vitro activity of cefpodoxime: a comparison with other oral cephalosporins. J Antimicrob Chemother. 1990; 25(4):541-50. DOI: 10.1093/jac/25.4.541. View

13.

Utsui Y, Inoue M, Mitsuhashi S . In vitro and in vivo antibacterial activities of CS-807, a new oral cephalosporin. Antimicrob Agents Chemother. 1987; 31(7):1085-92. PMC: 174876. DOI: 10.1128/AAC.31.7.1085. View

14.

Reynolds H . Bronchoalveolar lavage. Am Rev Respir Dis. 1987; 135(1):250-63. DOI: 10.1164/arrd.1987.135.1.250. View

15.

Hand W, Corwin R, Steinberg T, Grossman G . Uptake of antibiotics by human alveolar macrophages. Am Rev Respir Dis. 1984; 129(6):933-7. DOI: 10.1164/arrd.1984.129.6.933. View

16.

Wise R . The pharmacokinetics of the oral cephalosporins--a review. J Antimicrob Chemother. 1990; 26 Suppl E:13-20. DOI: 10.1093/jac/26.suppl_e.13. View